低剂量普罗巴诺洛尔与阿米特利普提林用于发作性偏头痛预防:随机对照试验评估有效性,安全性和成本效益
Vandana Roy1, Nasra Banu2, Girish Gulab Meshram2
1Department of Pharmacology, Maulana Azad Medical College and Associated Hospitals, New Delhi, 110002, India. roy.vandana@gmail.com.
Clinical drug investigation
|September 11, 2025
概括
低剂量普拉诺洛尔在预防偶发性偏头痛,减少头痛频率和几天方面比阿米林更有效. 然而,阿米特利普提林更具成本效益,尽管这两种药物都能耐受好,但副作用轻微.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 对于在偏头痛预防中使用普罗巴诺洛尔和阿米特利普提林的对比数据有限.
- 插曲性偏头痛显著影响生活质量和医疗保健成本.
研究的目的:
- 为了比较低剂量propranolol的疗效,安全性和成本效益与 amitriptyline用于偶发性偏头痛预防.
- 为了评估3个月的治疗结果.
主要方法:
- 一个随机的,受控的,开放的,前性试验,涉及60名先前未接受过预防治疗的偶发性偏头痛患者.
- 患者接受了低剂量的普拉诺洛尔 (80毫克/天) 或阿米特利普提林 (10毫克/天).
- 主要结果:减少每月头痛的频率;次要结果:≥50%的头痛减少,严重程度,残疾,救援药物使用,生活质量和成本效益.
主要成果:
- 甲醇显著降低了每月头痛的频率,远远超过阿米西林 (-3.67 vs -2.87天,P=0.03).
- 在接受普拉诺洛尔治疗的患者中,更高比例的患者在头痛日减少了≥50% (60%vs43.33%,P=0.02).
- 醇导致救援药物使用的减少更大 (P=0.01),但成本效益偏好了阿米.
结论:
- 低剂量普拉诺洛尔在偶发性偏头痛预防中表现出比阿米特利普提林更高的疗效.
- 这两种药物都耐受良好,有轻微的不良药物反应.
- 在这项试验中,阿米特利普提林被发现比普拉诺洛尔更具成本效益.
相关概念视频
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.6K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.6K
Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.1K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.1K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
1.4K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.4K
Antihypertensive Drugs: Types of β-Blockers
1.5K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.5K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
1.3K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.3K
Anxiolytic Drugs: Benzodiazepines and Buspirone
2.4K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
2.4K


